Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Change in Cash: 2018-2025

Historic Change in Cash for Autolus Therapeutics (AUTL) over the last 3 years, with Sep 2025 value amounting to -$37.7 million.

  • Autolus Therapeutics' Change in Cash rose 22.12% to -$37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$570.9 million, marking a year-over-year decrease of 242.13%. This contributed to the annual value of -$11.5 million for FY2024, which is 91.90% up from last year.
  • Autolus Therapeutics' Change in Cash amounted to -$37.7 million in Q3 2025, which was down 234.29% from $28.1 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Change in Cash registered a high of $519.2 million during Q1 2024, and its lowest value of -$429.7 million during Q4 2024.
  • For the 3-year period, Autolus Therapeutics' Change in Cash averaged around -$26.8 million, with its median value being -$39.4 million (2023).
  • Within the past 5 years, the most significant YoY rise in Autolus Therapeutics' Change in Cash was 1,417.59% (2024), while the steepest drop was 2,502.23% (2024).
  • Autolus Therapeutics' Change in Cash (Quarterly) stood at $219.4 million in 2022, then tumbled by 107.53% to -$16.5 million in 2023, then crashed by 2,502.23% to -$429.7 million in 2024, then climbed by 22.12% to -$37.7 million in 2025.
  • Its Change in Cash stands at -$37.7 million for Q3 2025, versus $28.1 million for Q2 2025 and -$131.6 million for Q1 2025.